Granted Patent
B2
US 12,252,475 · App. 18/414,958 · Granted Mar 18, 2025
Crystal forms of immunomodulators
Assignee:
Curis, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, including an anhydrous crystalline form, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.
Claims (11)
1. A method of therapeutically treating cancer in a subject in need thereof comprising administering to the subject an anhydrous crystalline compound having the structure of formula (I),
wherein:
the crystalline compound has 2θ values of 10.2±0.2, 15.2±0.2, 15.8±0.2, 16.5±0.2, 17.6±0.2, 18.1±0.2, 18.8±0.2, 20.5±0.2, 21.8±0.2, 22.3±0.2, 22.9±0.2, 24.2±0.2, 25.4±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 28.1±0.2, 28.8±0.2, 29.3±0.2, 30.4±0.2, 30.6±0.2, 32.0±0.2, 33.4±0.2, 33.6±0.2, 34.6±0.2, 35.8±0.2, 36.7±0.2, 37.3±0.2, 38.2±0.2, 38.6±0.2, and 39.2±0.2; and
the cancer is selected from mesothelioma, non-small cell lung cancer (NSCLC), small-cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, lung cancer, head and neck squamous cell carcinoma (HNSCC), cancer of the head or neck, Hodgkin's lymphoma, breast cancer, colon cancer, colorectal cancer, ovarian cancer, ovarian carcinoma, triple-negative breast cancer, primary ductal carcinoma, gastric cancer, glioblastoma, renal cancer, kidney cancer, multiple myeloma, leukemia, and lymphoma.
2. The method of claim 1 , wherein the cancer is selected from mesothelioma, non-small cell lung cancer (NSCLC), small-cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, and lung cancer.
3. The method of claim 1 , wherein the cancer is head and neck squamous cell carcinoma (HNSCC) or cancer of the head or neck.
4. The method of claim 1 , wherein the cancer is selected from breast cancer, colon cancer, colorectal cancer, ovarian cancer, ovarian carcinoma, triple-negative breast cancer, primary ductal carcinoma, gastric cancer, glioblastoma, renal cancer, and kidney cancer.
5. The method of claim 1 , wherein the cancer is lymphoma.
6. The method of claim 5 , wherein the lymphoma is Hodgkin's lymphoma, B-cell lymphomas, diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma, small lymphocytic non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, nodular sclerosis Hodgkin's lymphoma (NSHL), follicular non-Hodgkin's lymphoma, small lymphocytic non-Hodgkin's lymphoma, T cell lymphoma, cutaneous T-cell lymphoma, small lymphocytic lymphoma, lymphocytic lymphoma, or primary CNS lymphoma.
7. The method of claim 1 , wherein the cancer is leukemia.
8. The method of claim 7 , wherein the leukemia is chronic leukemia, acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, or chronic myeloblastic leukemia.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 9, 2024
From: YU, SHU
To: CURIS INC.
Reel/Frame 066430/0505 →
Priority Claims (1)
WO PCT/CN2017/104485
· Sep 29, 2017
· international
Continuity (4)
Continuation
16651830
References Cited (208)
US 3227725A
· Fernand et al.
· 1966
[cited by applicant]
US 5387585A
· Borer et al.
· 1995
[cited by applicant]
US 5665718A
· Godel et al.
· 1997
[cited by applicant]
US 8735553B1
· Li et al.
· 2014
[cited by applicant]
US 9771338B2
· Sasikumar et al.
· 2017
[cited by applicant]
US 20070197522A1
· Edwards et al.
· 2007
[cited by applicant]
US 20110275673A1
· Xiang et al.
· 2011
[cited by applicant]
US 20130022629A1
· Sharpe et al.
· 2013
[cited by applicant]
US 20150073024A1
· Sasikumar et al.
· 2015
[cited by applicant]
US 20200061030A1
· Sasikumar et al.
· 2020
[cited by applicant]
US 20230062570A1
· Sasikumar et al.
· 2023
[cited by applicant]
US 20230110077A1
· Sasikumar et al.
· 2023
[cited by applicant]
CN 105814028A
· 2016
[cited by applicant]
CN 111163772A
· 2020
[cited by applicant]
JP 2016532710A
· 2016
[cited by applicant]
JP 2016539662A
· 2016
[cited by applicant]
JP 2021501127A
· 2021
[cited by applicant]
KR 20160081897A
· 2016
[cited by applicant]
WO WO200114557A1
· 2001
[cited by applicant]
WO WO2002079499A1
· 2002
[cited by applicant]
WO WO2002086083A2
· 2002
[cited by applicant]
WO WO2003042402A2
· 2003
[cited by applicant]
WO WO2003070711A1
· 2003
[cited by applicant]
WO WO2004004771A1
· 2004
[cited by applicant]
WO WO2004056875A1
· 2004
[cited by applicant]
WO WO2005056550A2
· 2005
[cited by applicant]
WO WO2006121168A1
· 2006
[cited by applicant]
WO WO2006133216A2
· 2006
[cited by applicant]
WO WO2007075749A2
· 2007
[cited by applicant]
WO WO2008011557A2
· 2008
[cited by applicant]
WO WO2008039431A2
· 2008
[cited by applicant]
WO WO2008156712A1
· 2008
[cited by applicant]
WO WO2009006555A2
· 2009
[cited by applicant]
WO WO2009059162A1
· 2009
[cited by applicant]
WO WO2009105712A1
· 2009
[cited by applicant]
WO WO2010051447A1
· 2010
[cited by applicant]
WO WO2010077634A1
· 2010
[cited by applicant]
WO WO2011066389A1
· 2011
[cited by applicant]
WO WO2011082400A2
· 2011
[cited by applicant]
WO WO2011137587A1
· 2011
[cited by applicant]
WO WO2011161699A2
· 2011
[cited by applicant]
WO WO2012129564A2
· 2012
[cited by applicant]
WO WO2012168944A1
· 2012
[cited by applicant]
WO WO2013132317A1
· 2013
[cited by applicant]
WO WO2013144704A1
· 2013
[cited by applicant]
WO WO2014055897A2
· 2014
[cited by applicant]
WO WO2014059173A2
· 2014
[cited by applicant]
WO WO2014100079A1
· 2014
[cited by applicant]
WO WO2014110298A1
· 2014
[cited by applicant]
WO WO2014141104A1
· 2014
[cited by applicant]
WO WO2014147586A1
· 2014
[cited by applicant]
WO WO2015033299A1
· 2015
[cited by applicant]
WO WO2015033301A1
· 2015
[cited by applicant]
WO WO2016073470A1
· 2016
[cited by applicant]
WO WO2016142833A1
· 2016
[cited by applicant]
WO WO2016142852A1
· 2016
[cited by applicant]
WO WO2016142886A2
· 2016
[cited by applicant]
WO WO2017055860A1
· 2017
[cited by applicant]
WO WO2017079116A2
· 2017
[cited by applicant]
WO WO2018047143A1
· 2018
[cited by applicant]
WO WO2018051254A1
· 2018
[cited by applicant]
WO WO2018073754A1
· 2018
[cited by applicant]
WO WO2019067678A1
· 2019
[cited by applicant]
WO WO2019087087A1
· 2019
[cited by applicant]
WO WO2019087092A1
· 2019
[cited by applicant]
Alsaab et al., “PD-1 and PD-L1 Checkpoint Signaling Inhibition for CancerImmunotherapy: Mechanism, Combinations, and Clinical Outcome” Frontiers in Pharmacology, vol. 8, No. 561 (2017).
[cited by applicant]
Anderson et al., “Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation,” Immunity, 44(5): 989-1004 (2016).
[cited by applicant]
Ansell, “PD-1 Is Expressed on B-Cells in Waldenstrom Macroglobulinemia and Promotes Malignant Cell Viability and Proliferation” Blood, vol. 124, No. 21 (2014).
[cited by applicant]
Ardestani et al., “Cell death features induced in Leishmania major by 1,3,4-thiadiazole derivatives,” Exp Parasitol, 132(2): 116-122 (2012).
[cited by applicant]
Balbach et al., “Pharmaceutical evaluation of early development candidates “the 100 mg-approach”.” International Journal of Pharmaceutics 275.1-2 (2004): 1-12.
[cited by applicant]
Baldoni et al: “A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial”, Clinical Drug Investigation, Nov. 1, 2014.
[cited by applicant]
Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 66(1):1-19 (1977).
[cited by applicant]
Booher et al., “Combination of IRAK4 Inhibitor CA-4948 with BCL2 Inhibitor Venetoclax Induces Tumor Regression in an ABC-DLBCL Xenograft Model”, Blood, 130(1): 1534, (2017).
[cited by applicant]
Borg et al., “1,2,4-Oxadiazole Derivatives of Phenylalnine: Potential Inhibitors of Substance P Endopeptidase,” Eur. J. Med. Chem., 28(10):801-810 (1993).
[cited by applicant]
Brittain. “Polymorphism in pharmaceutical solids,” edited by H.G Brittain, D.J.W. Grant (chapter 1) p. 1-10 and J.K. Guillory (Chapter 5) p. 183-226 (1999).
[cited by applicant]
Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 12(7):945-954 (1995).
[cited by applicant]
Caira, “Crystalline polymorphism of organic compounds.” Design of Organic Solids (1998): 163-208.
[cited by applicant]
CAS Registry No. 1252104-30-5 (2013).
[cited by applicant]
CAS Registry No. 1356744-17-6 (2012).
[cited by applicant]
CAS Registry No. 146429-76-5 (2013).
[cited by applicant]
CAS Registry No. 1494629-78-5 (2013).
[cited by applicant]
CAS Registry No. 1496514-97-6 (2013).
[cited by applicant]
CAS Registry No. 1496518-51-4 (2013).
[cited by applicant]
CAS Registry No. 1557852-63-7 (2014).
[cited by applicant]
CAS Registry No. 1848907-06-1 (2016).
[cited by applicant]
CAS Registry No. 1848909-97-6 (2016).
[cited by applicant]
CAS Registry No. 1857027-85-0 (2016).
[cited by applicant]
CAS Registry No. 1868314-35-5 (2016).
[cited by applicant]
CAS Registry No. 1868388-36-6 (2016).
[cited by applicant]
CAS Registry No. 1868393-26-3 (2016).
[cited by applicant]
CAS Registry No. 1869758-25-7 (2016).
[cited by applicant]
CAS Registry No. 1870159-31-1 (2016).
[cited by applicant]
CAS Registry No. 1875311-16-2 (2016).
[cited by applicant]
CAS Registry No. 1875758-09-0 (2016).
[cited by applicant]
CAS Registry No. 1878569-90-4 (2016).
[cited by applicant]
CAS Registry No. 876710-85-9 (2006).
[cited by applicant]
Cedres et al., “Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)” Plos One DOI:10.1371 (2015).
[cited by applicant]
Censi et al., “Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs,” Molecules, 20(10): 18759-18776 (2015).
[cited by applicant]
Clinical Trial NCT 02812875., “A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas,” U.S. National Library of Medicine: 7 pages (2016).
[cited by applicant]
Clinical Trial NCT02671955., “A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer,” U.S. National Library of Medicine: 9 pages (2016).
[cited by applicant]
Curiel et al., “Blockade of B7-H1 improves myeloid dendritic cell-mediated anitumor immunity” Nature Medicine, vol. 9, No. 5 (2003).
[cited by applicant]
Database Registry Chemical Abstracts, STN Accession No. 172410-37-6.
[cited by applicant]
Database Registry Chemical Abstracts, STN Accession No. 197083-27-5.
[cited by applicant]
Dempke et al., “Second-and third-generation drugs for immuno-oncology treatment—The more the better?” Eur J Cancer, 74: 55-72 (2017).
[cited by applicant]
Deng et al., “A New VISTA on combination therapy for negative checkpoint regulator blockade” Journal for Immunotherapy of Cancer, 4(86): 1-7 (2016).
[cited by applicant]
Extended European Search Report for EP Application No. 16761169.8 mailed Jul. 2, 2019.
[cited by applicant]
Extended European Search Report for EP Application No. 16761184 dated Jun. 26, 2018.
[cited by applicant]
Extended European Search Report for EP Application No. 17862427.6 dated Jun. 5, 2020.
[cited by applicant]
Extended European Search Report for EP Application No. 18162983.3 dated Jun. 27, 2018.
[cited by applicant]
Extended European Search Report for EP Application No. 18863750 dated May 31, 2021.
[cited by applicant]
Extended European Search Report for EP Application No. 21209727.3 dated May 18, 2022.
[cited by applicant]
Golub, et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring,” Science, 286(5439): 531-537 (1999).
[cited by applicant]
Graham, “Clinical Trials of HIV Vaccines,” HIV Molecular Immunology Database 2000. Edited by: Korber BT, Brander C, Haynes BF, Koup R, Kuiken C, Moore JP, Walker BD, and Watkins D. Published by: Theoretical Biology and …
[cited by applicant]
Guo et al., “Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists,” Bioorg Med Chem Letts 22(7):2572-2578 (2012).
[cited by applicant]
Harvey, “Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer,” Nature, 96: 214-223 (2014).
[cited by applicant]
Hirayama “Handbook for preparation of crystal of organic compound”, Maruzen Co., Ltd 17-23, 37-40, 45-51, 57-65 (2008).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/IB2018/058526 dated May 14, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/CN 2017/104485 dated Jun. 29, 2018.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2014/064279 dated Dec. 12, 2014.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2016/051266 dated Jul. 8, 2016.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2016/051343 dated Jul. 28, 2016.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2017/056462 dated Jan. 10, 2018.
[cited by applicant]
International Search Report Written Opinion for International Application No. PCT/US2018/053052 dated Jan. 29, 2019.
[cited by applicant]
Jin, “Role of PD-1 in Regulating T-Cell Immunity,” Current Topics in Microbiology and Immunology, 350: 17-37 (2010).
[cited by applicant]
Lala et al., “Role of nitric oxide in tumor progression: lessons from experimental tumors”, Cancer and Metastasis Reviews 17: 91-106 (1998).
[cited by applicant]
Lazorchak et al., “Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer,” Cancer Immunol…
[cited by applicant]
Lee, “A practical guide to pharmaceutical polymorph screening & selection,” Asian J Pharm Sci, 9(4): 163-175 (2014).
[cited by applicant]
Lemercier et al., “VISTA regulates the development of protective antitumor immunity.” Cancer Research 74(7) (2014): 1933-1944.
[cited by applicant]
Liu et al., “Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses,” PNAS, 112(21): 6682-6687 (2015).
[cited by applicant]
Luo et al., “Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction,” Cell, 136(5): 823-837 (2009).
[cited by applicant]
Marechal et al., “1,2,4-oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome,” Curr Med Chem 20(18):2351-2362 (2013).
[cited by applicant]
Melero, “Evolving Synergistic Combinations of Targeted Immunotherapies to Combat Cancer”, Nature Reviews Cancer 15:457-472 (2015).
[cited by applicant]
Moussebois et al., “Synthese de Deux Nouveaux Acides Amines Phenoliques Comportant un Cycle 1,2,4-Oxadiazole,” Helv. Chim. ACTA, 60(1):237-242 (1977).
[cited by applicant]
National Institute of Health, “Cancer” Medline Plus, Retrieved from the internet, URL: https://medlineplus.gov/cancer.html. [online], [retrieved on Jun. 30, 2023].
[cited by applicant]
Newman, “Specialized Solid Form Screening Techniques,” Org Process Res Dev, 13(3): 457-471 (2012).
[cited by applicant]
Ozcan et al., “Oxadiazole-Isopropylamieds as Potent and Noncovalent Proteasome Inhibitors,” J. Med. Chem., 56(10):3783-3805 (2013).
[cited by applicant]
Palazzo et al., “1,2,4-Oxadiazoles—IV. Synthesis and Pharmacological Properties of a Series of Substituted Aminoalkyl-1,2,4-Oxadiazoles,” J. Med. Chem., 351-367 (1961).
[cited by applicant]
Patwardhan et al., “Structure-Activity Relationship Studies and in Vivo Activity of Guanidine-Based Sphingosine Kinase Inhibitors: Discovery of SphK1- and SphK2-Selective Inhibitors,” J. Med. Chem., 58(4):1879-1899 (201…
[cited by applicant]
Pedoeem et al., “Programmed Death-1 Pathway in Cancer and Autoimmunity,” Clinical Immunology, 153: 145-152 (2014).
[cited by applicant]
Rabadi et al., ““The role of VISTA in the tumor microenvironment”” Journal of Cancer Metastasis and Treatment, 8(24): 1-14 (2022).
[cited by applicant]
Rietz et al., “Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3),” J Med Chem, 64: 14757-14772 (2021).
[cited by applicant]
Sasikumar et al., “PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy,” Communications Biology, 4: 12 pages (2021).
[cited by applicant]
Shi et al., “The Role of PD-1 and PD-L1 in T-cell Immune Suppression in Patients with Hematological Malignancies,” Journal of Hematology & Oncology, 6(74): 1-6 (2013).
[cited by applicant]
Singhal et al., “Drug polymorphism and dosage form design: a practical perspective.” Advanced Drug Delivery Reviews 56.3 (2004): 335-347.
[cited by applicant]
Skrdla et al., “A Simple Quantitative FT-IR Approach for the Study of a Polymorphic Transformation Under Crystallization Slurry Conditions”, Journal of Pharmaceutical and Biomedical Analysis, 25(5-6): 731-739 (2001).
[cited by applicant]
Sureshbabu et al., “Synthesis of 1,2,4-oxadiazole-linked Orthogonally Urethane-Protected Dipeptide Mimetics,” Tetrahedron Letters, 49(35): 5133-5136 (2008).
[cited by applicant]
Swaika et al., “Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy” Molecular Immunology (2015).
[cited by applicant]
Tagliamento et al., “VISTA: A Promising Target for Cancer Immunotherapy?” Immuno Targets and Therapy, 10: 185-200 (2021).
[cited by applicant]
Takada, “API form screening and selection in drug discovery stage”, Pharm Stage, 6(10):20-25. (2007).
[cited by applicant]
Waldmann, “Effective Cancer Therapy Through Immunomodulation,” T Annu Rev Med, 57: 65-81 (2006).
[cited by applicant]
Wu et al., “VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses,” RSC Med Chem, 12: 1672-1679 (2021).
[cited by applicant]
Lazorchak et al., “An oral small molecule combination therapy targeting PD-L1, VISTA and Tim-3 immune inhibitory checkpoints exhibits enhanced anti-tumor efficacy in pre-clinical models of cancer,” Journal for Immunothe…
[cited by applicant]
Lazorchak et al., “An oral small molecule combination therapy targeting PD-L1, VISTA and Tim-3 immune inhibitory checkpoints exhibits enhanced anti-tumor efficacy in pre-clinical models of cancer,” Published by Curis No…
[cited by applicant]
Sasikumar et al., “Oral immune checkpoint antagonists targeting PD-L1/VISTA and PD-L1/Tim3 for cancer therapy,” Cancer Research 76.14 (Jul. 31, 2016).
[cited by applicant]
Sasikumar et al., “Oral immune checkpoint antagonists targeting PD-L1/VISTA and PD-L1/Tim3 for cancer therapy,” Published by Curis Oct. 1, 2019.
[cited by applicant]
U.S. Appl. No. 15/556,800.
[cited by applicant]
U.S. Appl. No. 16/945,854.
[cited by applicant]
U.S. Appl. No. 17/962,976.
[cited by applicant]
U.S. Appl. No. 15/298,539.
[cited by applicant]
U.S. Appl. No. 15/713,671.
[cited by applicant]
U.S. Appl. No. 16/192,030.
[cited by applicant]
U.S. Appl. No. 16/806,872.
[cited by applicant]
U.S. Appl. No. 17/192,279.
[cited by applicant]
U.S. Appl. No. 17/981,695.
[cited by applicant]
U.S. Appl. No. 18/747,813.
[cited by applicant]
U.S. Appl. No. 16/343,681.
[cited by applicant]
U.S. Appl. No. 16/761,162.
[cited by applicant]
U.S. Appl. No. 18/516,458.
[cited by applicant]
U.S. Appl. No. 16/651,830.
[cited by applicant]
U.S. Appl. No. 17/350,445.
[cited by applicant]
U.S. Appl. No. 18/101,387.
[cited by applicant]
U.S. Appl. No. 16/755,439.
[cited by applicant]
U.S. Appl. No. 17/461,512.
[cited by applicant]
U.S. Appl. No. 18/197,414.
[cited by applicant]
U.S. Appl. No. 16/761,964.
[cited by applicant]
U.S. Appl. No. 17/960,586.
[cited by applicant]
Cited By (1)